Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of type 1 diabetes for up to 3 months at screening~* Insulin dependency~* Fasting C-peptide levels \>= 0.22 nmol/L~* Presence of at least 1 of the diabetes-related autoantibodies (IA-2A, GAD or IA)~Exclusion Criteria:~* Pregnancy or intent to conceive in the next 2 years~* Significant diseases that could affect response to treatment, such as tumors, psychiatric disorders, substance abuse, severe allergies or diabetes-related complications.~* Patient has immune deficiency or receives immuno-suppressive or cytotoxic drugs.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- DiaPep277 (Type: EXPERIMENTAL): DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
- Placebo (Type: PLACEBO_COMPARATOR): Mannitol 40 mg in 0.5 mL lipid emulsion.

Based on this trial design, predict the completion outcome and termination type (if applicable).